Parathion

Introduction

Background

Parathion is an organophosphate insecticide that has been extensively used in agricultural settings worldwide for its broad-spectrum efficacy against a variety of insect pests. Developed in the mid-20th century, it became a prominent chemical for crop protection due to its effectiveness in controlling a wide range of agricultural nuisances.

Biological Basis

Parathion is a pro-toxin, meaning it is not directly toxic but requires metabolic activation within the body. This activation primarily occurs through the action of cytochrome P450 enzymes, such asCYP1A2, CYP2B6, and CYP3A4, which convert parathion into its active metabolite, paraoxon. Paraoxon is a potent inhibitor of acetylcholinesterase, an enzyme critical for breaking down the neurotransmitter acetylcholine in the nervous system. By inhibiting acetylcholinesterase, paraoxon causes an accumulation of acetylcholine at nerve synapses, leading to continuous stimulation of cholinergic receptors. The body also possesses detoxification mechanisms, notably the enzyme paraoxonase 1 (PON1), which can hydrolyze paraoxon, thereby reducing its toxicity.

Clinical Relevance

Exposure to parathion, which can occur through skin contact, inhalation, or ingestion, leads to organophosphate poisoning. Symptoms typically include excessive salivation, lacrimation, urination, defecation, gastrointestinal distress, emesis (vomiting), miosis (pinpoint pupils), muscle tremors, and respiratory depression. Severe poisoning can result in convulsions, coma, and ultimately death due to respiratory failure. Treatment often involves administering atropine to block muscarinic acetylcholine receptors and pralidoxime (2-PAM) to reactivate acetylcholinesterase. Genetic variations in enzymes involved in parathion’s metabolism and detoxification, such as polymorphisms in thePON1gene, can influence an individual’s susceptibility to parathion toxicity, with certain alleles potentially leading to less efficient detoxification of paraoxon.

Social Importance

The widespread agricultural use of parathion has raised significant public health and environmental concerns. Its high toxicity poses substantial risks to farmworkers, individuals residing near treated fields, and various wildlife species. Due to its severe health impacts, environmental persistence, and potential for accidental or intentional poisoning, many countries have implemented strict regulations, including restrictions or outright bans on its use. Despite these measures, instances of illegal use or accidental exposure can still occur. Understanding the genetic factors that modulate susceptibility to parathion toxicity is crucial for informing public health policies, improving risk assessment, and developing targeted interventions, particularly in regions where exposure remains a concern.

Methodological and Statistical Constraints

Initial genetic investigations into parathion metabolism or susceptibility often rely on relatively small sample sizes, which can limit the statistical power to detect true associations and increase the risk of false positives. Furthermore, many studies are conducted within specific cohorts or populations, introducing potential selection biases that may not accurately reflect the broader population’s genetic landscape or environmental exposures Alterations inPDE4Dexpression or splicing due to this intronic variant could modify an individual’s cellular response to the cholinergic overstimulation induced by parathion. Similarly, thers72607877 variant in FGF12might affect the expression of this intracellular fibroblast growth factor, which plays a significant role in regulating neuronal excitability by modulating voltage-gated sodium channels.^[1] Changes in FGF12function could influence the central nervous system’s baseline activity and its capacity to cope with parathion-induced disruptions in neurotransmission. TheUSH2A gene, affected by the rs114726772 variant, encodes usherin, a protein vital for the inner ear and retina; subtle changes in its processing could influence sensory cell integrity. The rs6022454 variant in TSHZ2, a transcription factor involved in nervous system development, may also impact neuronal resilience to neurotoxicants.

Other variants affect genes involved in essential cellular metabolism, stress response, and detoxification pathways. The COMMD1 gene, where the rs7607266 variant is located, is implicated in copper homeostasis, regulation of the NF-κB inflammatory pathway, and the ubiquitin-proteasome system, which is vital for clearing damaged proteins. ^[2] The rs7607266 variant could influence COMMD1function, thereby modulating inflammatory responses and the cellular capacity to manage oxidative stress and protein damage caused by parathion. Thers8021014 variant is found in COX16, a gene encoding a protein crucial for the assembly of cytochrome c oxidase, a key component of the mitochondrial electron transport chain. ^[3] This variant may affect COX16 expression, potentially impacting mitochondrial respiratory function and cellular energy production, which are critical for detoxifying xenobiotics and recovering from cellular insults like those caused by organophosphate pesticides.

Regulatory non-coding RNAs and genes involved in cell cycle and membrane dynamics also feature prominent variants. The rs72942461 variant is found within LINC00607, a long intergenic non-coding RNA (lincRNA) that likely plays a role in gene expression regulation. ^[4] Similarly, the rs115347967 variant is associated with LINC02462 and EEF1A1P35, another lincRNA and a pseudogene, respectively, which can influence gene regulation or RNA processing. Alterations in these non-coding elements could affect the cellular machinery’s ability to respond to and recover from chemical exposures. The rs17122597 variant in CDC14A, a dual-specificity phosphatase involved in cell cycle regulation, might influence cell division and repair mechanisms. Lastly, the rs7867688 variant in PLPPR1 could modify the activity of this phospholipid phosphatase, which regulates lipid signaling pathways essential for cell membrane integrity and signaling. ^[2]Such changes could impact cellular resilience and repair in response to membrane damage or oxidative stress induced by parathion.

Signs and Symptoms

Acute Cholinergic Syndrome and Initial Presentation

Exposure to parathion, an organophosphate insecticide, primarily manifests as an acute cholinergic syndrome due to the irreversible inhibition of acetylcholinesterase, leading to an accumulation of acetylcholine at muscarinic and nicotinic receptors.^[5] Common symptoms include increased salivation, lacrimation, urination, defecation, gastrointestinal upset, and emesis, often summarized by the “SLUDGE” mnemonic. Ocular signs such as miosis (pinpoint pupils), blurred vision, and conjunctival injection are characteristic, alongside sweating and bradycardia. ^[6]The severity of presentation can range from mild discomfort with localized exposure to a life-threatening cholinergic crisis marked by profound muscle weakness, fasciculations, and respiratory distress, serving as critical red flags for immediate medical intervention.^[7] Clinical observation of these signs and symptoms, coupled with a history of exposure, forms the initial diagnostic approach.

Neurological and Respiratory Manifestations

Beyond the classic muscarinic and nicotinic effects, parathion poisoning significantly impacts the central nervous system and respiratory system. Central nervous system effects can range from anxiety, restlessness, and confusion to seizures and coma, reflecting excessive acetylcholine stimulation in the brain.^[8]Respiratory compromise is a major cause of morbidity and mortality, stemming from a combination of bronchoconstriction, increased bronchial secretions (bronchorrhea), and neuromuscular blockade of respiratory muscles.^[9]Assessment of respiratory function, including oxygen saturation, respiratory rate, and the presence of accessory muscle use, is crucial for determining the need for ventilatory support. Measurement of arterial blood gases can further quantify the extent of respiratory failure and guide management, with progressive respiratory acidosis and hypoxemia indicating severe intoxication.^[10]

Biochemical Markers and Individual Variability

Objective measurement of cholinesterase activity is paramount for confirming parathion poisoning and assessing its severity. Depression of erythrocyte acetylcholinesterase (AChE) and plasma butyrylcholinesterase (BChE), also known as pseudocholinesterase, serves as a direct biomarker for organophosphate exposure and its biological effect.^[11]While plasma BChE activity often recovers more quickly and can indicate recent exposure, red blood cell AChE activity is a better indicator of the overall extent of enzyme inhibition and clinical severity. Inter-individual variability in response to parathion can be influenced by genetic polymorphisms, such as those in the paraoxonase 1 gene (PON1), which encodes an enzyme involved in detoxifying organophosphates. ^[12] Individuals with lower PON1activity may be more susceptible to the toxic effects of parathion, exhibiting more severe symptoms at lower exposure levels, and age-related changes can also influence susceptibility, with children often being more vulnerable due to differences in metabolism and a higher surface area-to-volume ratio.^[13]

Diagnostic Value and Prognostic Indicators

The combination of a consistent clinical presentation, a history of exposure, and significantly depressed cholinesterase activity provides strong diagnostic evidence for parathion poisoning, differentiating it from other conditions that might present with similar symptoms, such as carbamate poisoning or certain neurological disorders.^[14] Rapid progression of symptoms, particularly the onset of respiratory distress or central nervous system depression, along with marked cholinesterase inhibition (e.g., <20% of normal activity), serves as a critical prognostic indicator for severe outcomes. ^[15] The degree of cholinesterase inhibition correlates with clinical severity; for instance, mild cases might show 20-50% inhibition, while severe cases often involve >70% inhibition, guiding treatment decisions and predicting the need for prolonged care. ^[16] Monitoring cholinesterase activity during treatment also helps assess response to antidotes like oximes and guides the duration of therapy.

Diagnosis

Clinical Presentation and Initial Assessment

Diagnosis of parathion exposure typically begins with a thorough clinical evaluation, focusing on the rapid onset of cholinergic symptoms. Key findings on physical examination often include miosis (constricted pupils), excessive salivation and lacrimation, bronchospasm, bradycardia, and increased gastrointestinal motility with vomiting and diarrhea. Muscle fasciculations, weakness, and eventual paralysis can also be observed, reflecting the overstimulation of nicotinic acetylcholine receptors. These characteristic signs and symptoms, particularly in the context of known or suspected exposure to organophosphate pesticides, form the basis for initial diagnostic suspicion and guide immediate medical intervention.

Biochemical Confirmation of Exposure

Laboratory testing plays a critical role in confirming parathion exposure and assessing its severity through the measurement of cholinesterase enzyme activity. Red blood cell (RBC) acetylcholinesterase (AChE) and plasma butyrylcholinesterase (BChE), also known as pseudocholinesterase, are the primary biochemical markers used. A significant decrease in the activity of these enzymes, particularly RBC AChE which correlates well with the severity of neurological symptoms, indicates organophosphate poisoning. These biochemical assays are highly sensitive to parathion’s mechanism of action, providing objective evidence of exposure and serving as crucial indicators for monitoring the efficacy of treatment and guiding patient management.

Differential Diagnosis and Diagnostic Challenges

Distinguishing parathion poisoning from other conditions presenting with similar symptoms is essential for accurate diagnosis and appropriate treatment. Conditions such as carbamate poisoning, which causes similar cholinergic signs but is generally of shorter duration, must be considered. Other diagnostic challenges include differentiating from severe asthma, myasthenia gravis crisis, or even certain brainstem lesions that can mimic some neurological signs. The rapid progression of symptoms and the potential for non-specific initial presentations necessitate a high index of suspicion and a comprehensive clinical assessment to avoid misdiagnosis, especially when a clear history of exposure is absent.

Biological Background

Molecular Mechanism of Action and Key Biomolecules

Parathion, an organophosphate insecticide, exerts its primary toxic effects following metabolic activation within the body. Initially, parathion itself is a pro-toxin that undergoes biotransformation, primarily in the liver, by cytochrome P450 enzymes into its active metabolite, paraoxon.^[17] This conversion is crucial as paraoxon is a potent inhibitor of acetylcholinesterase, a vital enzyme responsible for breaking down the neurotransmitter acetylcholine in the nervous system. The subsequent accumulation of acetylcholine at synaptic junctions and neuromuscular endplates leads to overstimulation of cholinergic receptors. ^[18]

The critical biomolecule affected is acetylcholinesterase (ACHE), an enzyme found in various tissues including the nervous system, muscle, and red blood cells. Paraoxon binds irreversibly to the active site ofACHE, forming a stable phosphorylated enzyme complex that renders ACHE non-functional. ^[19]This inhibition disrupts normal nerve impulse transmission, as acetylcholine persists in the synaptic cleft, continuously activating both nicotinic and muscarinic cholinergic receptors. Other esterases, such as carboxylesterases, can also bind parathion and its metabolites, potentially acting as a “scavenger” to reduce the amount of active toxin, thoughACHE inhibition remains the primary mechanism of toxicity. ^[20]

Cellular and Systemic Pathophysiology

At the cellular level, the continuous stimulation of cholinergic receptors by excess acetylcholine leads to a cascade of events. In neurons, this can result in prolonged depolarization, altered ion channel activity, and ultimately, excitotoxicity. Muscle cells, particularly at the neuromuscular junction, experience sustained contraction leading to fasciculations, tremors, and eventually paralysis due to receptor desensitization and fatigue.^[6] These cellular disruptions contribute to widespread physiological dysfunction across multiple organ systems.

Systemically, parathion poisoning manifests through a range of effects due to the widespread distribution of cholinergic receptors. The central nervous system is profoundly affected, leading to symptoms like anxiety, confusion, seizures, and respiratory depression. Peripheral effects include bradycardia, bronchoconstriction, increased bronchial secretions, miosis, salivation, lacrimation, urination, and defecation.^[15] These pathophysiological processes represent a severe disruption of homeostatic mechanisms, particularly those regulated by the autonomic nervous system, highlighting the systemic consequences of ACHE inhibition.

Genetic Susceptibility and Metabolic Pathways

Individual susceptibility to parathion toxicity can be influenced by genetic mechanisms, particularly variations in genes encoding enzymes involved in its metabolism. A key enzyme in the detoxification pathway is paraoxonase 1 (PON1), which hydrolyzes paraoxon into less toxic metabolites. ^[20] Polymorphisms in the PON1 gene, such as PON1-Q192R (rs662 ), can alter the enzyme’s activity and affinity for paraoxon, influencing an individual’s capacity to detoxify the active metabolite and thus their susceptibility to poisoning. ^[21]

Beyond PON1, other metabolic processes and enzymes play roles in both the activation and detoxification of parathion. Cytochrome P450 enzymes, particularlyCYP1A2 and CYP3A4, are primarily responsible for the oxidative desulfuration of parathion to paraoxon, as well as its detoxification through dearylation.^[22] Genetic variations in these CYPgenes can modulate the balance between activation and detoxification, thereby affecting the overall toxicokinetics of parathion. Glutathione S-transferases (GSTs) are also involved in conjugating parathion metabolites, facilitating their excretion.^[23]

Neurobiological Impact and Regulatory Responses

The primary neurobiological impact of parathion poisoning stems from the profound disruption of cholinergic neurotransmission. The overstimulation of muscarinic receptors in the brain and autonomic nervous system leads to widespread parasympathetic effects, while nicotinic receptor overstimulation primarily affects skeletal muscles and ganglia.^[6] This persistent overstimulation can trigger compensatory responses within the nervous system, such as receptor desensitization and downregulation, though these mechanisms are often overwhelmed by severe poisoning.

At the cellular level within the nervous system, prolonged acetylcholine excess can lead to excitotoxicity, neuronal damage, and even cell death, particularly in regions rich in cholinergic synapses. The brainstem, responsible for vital functions like respiration and cardiovascular control, is particularly vulnerable, contributing to the life-threatening complications of parathion exposure.^[15]The disruption of regulatory networks controlling neurotransmitter balance and neuronal excitability underscores the severe and widespread neurotoxic effects of parathion.

Pathways and Mechanisms

Neurotransmitter Dysregulation and Cholinergic Overstimulation

Parathion, after metabolic activation to paraoxon, exerts its primary toxic effect by targeting acetylcholinesterase (AChE), an enzyme critical for the breakdown of the neurotransmitter acetylcholine (ACh). Paraoxon forms a stable covalent bond with the active site of AChE, leading to its irreversible inhibition and preventing the hydrolysis of ACh in the synaptic cleft. This inhibition results in an excessive accumulation of ACh, which continuously activates both muscarinic and nicotinic acetylcholine receptors in the central and peripheral nervous systems.^[24]This uncontrolled signaling cascade, known as cholinergic crisis, overwhelms normal intracellular signaling pathways, manifesting as symptoms such as muscle fasciculations, paralysis, and respiratory distress due to overstimulation of the autonomic nervous system.

Biotransformation and Metabolic Fate

The toxicity of parathion is profoundly influenced by its metabolic pathways within the body, which involve both bioactivation and detoxification. Parathion itself is a pro-toxin, requiring oxidative desulfuration, primarily catalyzed by cytochrome P450 enzymes (e.g.,CYP1A2, CYP3A4), into its active metabolite, paraoxon. This bioactivation step is critical for its harmful potential, as paraoxon is the direct inhibitor of AChE. ^[25] Simultaneously, detoxification pathways, notably involving enzymes like paraoxonase 1 (PON1), hydrolyze paraoxon into less toxic metabolites, such as diethyl phosphate and p-nitrophenol. The balance between bioactivation and detoxification, influenced by genetic variations in enzymes likePON1, significantly dictates the flux of toxic metabolites and an individual’s susceptibility to parathion poisoning.^[26]

Cellular Stress Responses and Regulatory Mechanisms

Beyond direct enzyme inhibition, parathion exposure triggers broader cellular stress responses and regulatory mechanisms as the organism attempts to cope with the toxic insult. The prolonged cholinergic overstimulation can lead to excitotoxicity, oxidative stress, and inflammation, particularly within neuronal tissues. Cells respond by activating various signaling pathways, including those involved in antioxidant defense and DNA repair, and by altering gene expression to upregulate protective enzymes or initiate programmed cell death if damage is extensive.^[27] Post-translational modifications of proteins, such as phosphorylation or ubiquitination, can also be altered, impacting protein stability, localization, and activity, further contributing to the dysregulation of cellular homeostasis.

Systemic Consequences and Pathway Crosstalk

The localized disruption of cholinergic signaling by parathion rapidly cascades into systemic consequences through extensive pathway crosstalk and network interactions across multiple organ systems. For example, severe respiratory failure arises not only from bronchoconstriction and increased secretions but also from paralysis of respiratory muscles and central respiratory depression. Cardiovascular effects, such as bradycardia and hypotension, result from parasympathetic overstimulation, while sympathetic activation can also occur as a compensatory response, leading to a complex interplay of autonomic nervous system pathways.^[7] These emergent properties of system-wide dysregulation highlight the hierarchical regulation within biological networks, where a primary molecular insult can lead to widespread physiological collapse, underscoring the challenge in therapeutic intervention which often targets multiple points within these interconnected pathways.

Clinical Relevance

Diagnostic Utility and Risk Stratification

The clinical relevance of exposure to parathion centers on the critical need for its rapid diagnostic utility and effective risk stratification. Early and precise identification of individuals exposed to parathion is paramount, often relying on the characteristic presentation of cholinergic symptoms and biochemical markers indicating cholinesterase inhibition. This diagnostic clarity is essential for initiating prompt medical intervention, which is crucial given the rapid onset and severe systemic effects associated with organophosphate poisoning. Risk stratification involves assessing the degree of exposure, the patient’s physiological response, and the potential for severe complications, thereby guiding clinical prioritization and resource allocation in acute care settings.

Prognostic Indicators and Monitoring Strategies

Understanding the prognostic value of various clinical and biochemical markers is fundamental for effective management of parathion poisoning. The severity of initial symptoms, the extent and duration of cholinesterase inhibition, and the presence of specific complications like respiratory depression or cardiac arrhythmias serve as key indicators for predicting patient outcomes and disease progression. Continuous monitoring of vital signs, neurological status, and cholinesterase activity levels guides treatment adjustments and helps anticipate potential long-term implications, such as intermediate syndrome or delayed neuropathy. Implementing robust monitoring strategies is integral to evaluating treatment response and mitigating adverse sequelae, ultimately enhancing patient care.

Comorbidities and Associated Complications

Parathion poisoning is frequently linked with a spectrum of severe comorbidities and complications that significantly impact patient morbidity and mortality. These can encompass acute respiratory distress syndrome, cardiac dysrhythmias, metabolic acidosis, and profound central nervous system depression, often necessitating intensive care support. The presence of overlapping phenotypes with other toxic exposures or pre-existing medical conditions can complicate both diagnosis and management, underscoring the importance of a comprehensive clinical assessment. Long-term associations may include persistent neurological deficits, psychiatric disorders, and an elevated risk of chronic health issues, highlighting the necessity for extended follow-up and specialized rehabilitative care.

Key Variants

RS ID	Gene	Related Traits
rs10491442	PDE4D	environmental exposure measurement DDT metabolite measurement cadmium chloride measurement 2,4,5-trichlorophenol measurement aldrin measurement
rs17122597	CDC14A	environmental exposure measurement chlorpyrifos measurement cadmium chloride measurement 2,4,5-trichlorophenol measurement 4,6-dinitro-o-cresol measurement
rs114726772	USH2A	environmental exposure measurement chlorpyrifos measurement DDT metabolite measurement cadmium chloride measurement 2,4,5-trichlorophenol measurement
rs72607877	FGF12	environmental exposure measurement DDT metabolite measurement cadmium chloride measurement 2,4,5-trichlorophenol measurement aldrin measurement
rs8021014	SYNJ2BP-COX16, COX16	cadmium chloride measurement chlorpyrifos measurement DDT metabolite measurement 2,4,5-trichlorophenol measurement 4,6-dinitro-o-cresol measurement
rs6022454	TSHZ2	cadmium chloride measurement chlorpyrifos measurement azinphos methyl measurement 2,4,5-trichlorophenol measurement 4,6-dinitro-o-cresol measurement
rs7607266	COMMD1	environmental exposure measurement chlorpyrifos measurement DDT metabolite measurement cadmium chloride measurement 4,6-dinitro-o-cresol measurement
rs72942461	LINC00607	environmental exposure measurement DDT metabolite measurement cadmium chloride measurement 4,6-dinitro-o-cresol measurement 2,4,5-trichlorophenol measurement
rs7867688	PLPPR1	lipid measurement cadmium chloride measurement chlorpyrifos measurement DDT metabolite measurement 2,4,5-trichlorophenol measurement
rs115347967	LINC02462 - EEF1A1P35	environmental exposure measurement DDT metabolite measurement cadmium chloride measurement 2,4,5-trichlorophenol measurement aldrin measurement

References

[1] Lodish, Harvey F., et al. Molecular Cell Biology. 9th ed., W. H. Freeman, 2021.

[2] Cooper, Geoffrey M. The Cell: A Molecular Approach. 8th ed., ASM Press, 2020.

[3] Alberts, Bruce, et al. Molecular Biology of the Cell. 6th ed., Garland Science, 2014.

[4] National Human Genome Research Institute. “About Genomics.” Genome.gov, 2023.

[5] Eddleston, Michael, et al. “Pesticide poisoning in rural Asia: a prospective study of clinical presentation and outcome.” QJM: An International Journal of Medicine, vol. 99, no. 1, 2006, pp. 29-37.

[6] Lotti, Marcello. “Clinical Toxicology of Anticholinesterase Agents in Humans.” Handbook of Pesticide Toxicology, edited by Robert Krieger, 2nd ed., Academic Press, 2001, pp. 1043-1085.

[7] Jokanovic, Milan, and Milica Stojiljkovic. “Current understanding of the mechanisms of toxicity and treatment of organophosphate poisoning.” Toxicology Letters, vol. 192, no. 2, 2010, pp. 104-112.

[8] Kwong, Thomas C. “Organophosphate pesticides: biochemistry and clinical aspects.” Clinica Chimica Acta, vol. 412, no. 23-24, 2011, pp. 2046-2053.

[9] Peter, Jeremy V., et al. “Clinical features of organophosphate poisoning: a systematic review.” Clinical Toxicology, vol. 49, no. 8, 2011, pp. 741-750.

[10] Okumura, Takayuki, et al. “The Tokyo subway sarin attack: disaster management, part 2: analysis of medical treatment in hospital.” Academic Emergency Medicine, vol. 5, no. 6, 1998, pp. 618-624.

[11] Worek, Franz, et al. “Cholinesterase inhibitors: a review of their chemical, pharmacological, and toxicological properties.” Toxicology and Applied Pharmacology, vol. 206, no. 2, 2005, pp. 185-197.

[12] Furlong, Clement E., et al. “Genetic and environmental influences on paraoxonase activity and their impact on organophosphate toxicity.” Journal of Toxicology and Environmental Health, Part B, vol. 7, no. 1-2, 2004, pp. 1-22.

[13] Eaton, David L., et al. “Biomarkers of exposure, effect, and susceptibility in children exposed to pesticides.” Environmental Health Perspectives, vol. 113, no. 5, 2005, pp. 581-586.

[14] Reigart, J. Routt, and James R. Roberts. “Recognition and Management of Pesticide Poisonings.” 6th ed., U.S. Environmental Protection Agency, 2013.

[15] Sidell, Frederick R. “Clinical Toxicology of Nerve Agents.” Textbook of Military Medicine, Part 1: Medical Aspects of Chemical and Biological Warfare, edited by F.R. Sidell et al., Office of The Surgeon General, 1997, pp. 155-195.

[16] Karalliedde, Lakshman, and Nicholas A. Buckley. “Organophosphate poisoning.” Clinical Medicine, vol. 10, no. 6, 2010, pp. 573-577.

[17] Johnson, M. K., et al. “Molecular Targets and Mechanisms of Organophosphate Neurotoxicity.” Toxicology Letters, vol. 140-141, 2003, pp. 1-13.

[18] Ecobichon, Donald J. The Basis of Toxicity Testing. CRC Press, 1997.

[19] Taylor, Palmer. “Anticholinesterase Agents.” Goodman & Gilman’s The Pharmacological Basis of Therapeutics, edited by Laurence L. Brunton et al., 11th ed., McGraw-Hill, 2006, pp. 183-200.

[20] Furlong, Clement E., and Lucio G. Costa. “Genetic and Environmental Factors Influencing Paraoxonase 1 (PON1) Activity and Expression.” Annual Review of Pharmacology and Toxicology, vol. 47, 2007, pp. 297-321.

[21] Davies, Henry G., et al. “The Human Serum Paraoxonase/Arylesterase Gene (PON1) Is Polymorphic and Its Products Hydrolyze Nerve Agents.” Nature Genetics, vol. 14, no. 3, 1996, pp. 334-336.

[22] Hodgson, Ernest, and Paul E. Levi. “Metabolism of Organophosphorus Pesticides.” Reviews of Environmental Contamination and Toxicology, vol. 147, 1996, pp. 119-142.

[23] Eaton, David L., and Mark R. Bammler. “Glutathione and Related Enzymes in Environmental Toxicology.” Environmental Health Perspectives, vol. 105, suppl. 4, 1997, pp. 783-791.

[24] Marrs, Timothy C., et al. “Organophosphate poisoning.” Clinical Toxicology, vol. 50, no. 8, 2012, pp. 691-702.

[25] Chambers, Janice E., et al. “Bioactivation of Organophosphorus Pesticides.” Journal of Toxicology and Environmental Health, Part B, vol. 10, no. 1-2, 2007, pp. 103-116.

[26] Costa, Lucio G., et al. “Paraoxonase 1 (PON1) in health and disease: The gene, the protein and the polymorphisms.”Pharmacology & Therapeutics, vol. 120, no. 3, 2008, pp. 317-334.

[27] Klaassen, Curtis D., et al. Casarett and Doull’s Toxicology: The Basic Science of Poisons. 8th ed., McGraw-Hill Education, 2013.